Expression Of The MDR1 Gene Product P‐glycoprotein In Childhood Neuroblastoma

Below is result for Expression Of The MDR1 Gene Product P‐glycoprotein In Childhood Neuroblastoma in PDF format. You can download or read online all document for free, but please respect copyrighted ebooks. This site does not host PDF files, all document are the property of their respective owners.

Pglycoprotein (P-gp) and drug resistance time for reappraisal?

apy for neuroblastoma. N. drug resistance gene product (P-glycoprotein) Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell

Multidrug Resistance and Malignancy in Human Osteosarcoma1

expression of the MDR1 gene product P-glycoprotein is the most impor tant predictor of an adverse clinical course in patients with osteosarcoma treated with chemotherapy. In this study, we analyzed the relationship between P-glycoprotein expression and local aggressiveness and systemic dissemination of multidrug-resistant (MDKl human

Expression of multidrug transporter MRP4/ABCC4 is a marker of

strong evidence of a role for MRP1 (but not MDR1 P-glycoprotein) in mediating the drug-resistant phenotype of this aggressive childhood cancer (6). In addition, we have shown that MYCN may mediate poor response to treatment by up-regulating expression of the MRP1 gene (7 9). We have now examined the expression of other

MDR1 gene expression in endometrial carcinoma

expression (40±33)% vs. 11±20%, P=0.04). P-glycoprotein immunoreactiv-ity was found to be less with advanced age in endometrial carcinoma. However, premenopausal patients were found to have a significantly higher P-glycoprotein expression. KEYWORDS: immunohistochemistry, endometrial cancer, multidrug resist-ance, P-glycoprotein.

Dodging the bullet: therapeutic resistance mechanisms in

in neuroblastoma[60,80,81], CD133 expression in astrocytomas[82], or SORCIN or MDK expression in acute lymphoblastic leukemia[83,84]. There has also been concern that the tumor cells upregulate ABC protein expression in response to therapy, resulting in higher expression during therapy or at recurrence[60,85-87].

BIRICODAR (VX-710; Incelª): an effective chemosensitizer in

neuroblastoma. To clarify the nature of multidrug resistance (MDR) in this tumour a series of six neuroblastoma cell lines have been characterized with regard to P-glycoprotein, MRP and LRP expression using immunocytochemistry and expression of MDR1, MRP, LRP and topoisomerase II genes using reverse transcription polymerase chain reaction (RT-PCR).

Modulators of MRP1 promoter in Neuroblastoma cell lines-1

childhood cancermaking it one of the most common early childhood malignancies. (Elattar, 2003). At the children s cancer hospital 57357 Egypt, Neuroblastoma is the fourth most common type of cancer accounting for 15% of the patients admitted between 2007 and 2010 (fig 1).In other words the hospital receives around a 100 patients annually(fig 2).

Michael M. Gottesman

sistance in cultured cancer cells was the expression of an energy-dependent drug efflux pump, known alternatively as P-glycoprotein (P-gp) or the multidrug trans-porter (14,15). This efflux pump, the product of the MDR1 gene in the human (16) and the product of two different related genes, mdr1a and mdr1b in the mouse

P-glycoprotein as a Drug Target in the Treatment of Multidrug

THE BIOLOGY OF P-GLYCOPROTEIN The gene encoding Pgp belongs to the MDR multigene family [22], which consists of two highly homologous genes MDR1 and MDR2 (formerly designated as MDR3) situated on chromosome 7q21.1 in humans [41]. Transfection studies have demonstrated that MDR1 cDNA consistently

The Pharmacological Phenotype of Combined Multidrug

lymphocytic leukemia has been documented. The role of MDR1 gene expression in the clinical resistance of solid tumors, however, is currently not firmly established (13). Nonetheless, in several malig-nancies, such as acute myelocytic leukemia, various childhood can-cers, and advanced breast cancer, overexpression of the MDR1 gene


1 Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma 107 C. Dhooge, B. De Moerloose, Y. Benoit, N. Van Roy, J. Philippé, G. Laureys Cancer 1997; 80: 1250-1257 2 Discrepant flow cytometric expression and function of P-glycoprotein in neuroblastic tumors 116

The expression of P-glycoprotein is causally related to a

tumors, detectable levels of expression of P-glycoprotein have been associated with a significantly poor prognosis in neuroblastoma (Chan et al., 1991), in childhood soft-

Expression of the MDR1 gene product Pâ glycoprotein in

Expression of the MDR1 Gene Product P-Glycoprotein in Childhood Neuroblastoma Catharina R. M. Dhooge, M.D.1 BACKGROUND. In cancer treated with chemotherapy, multidrug resistance is char-Barbara M. J. De Moerloose, M.D.2 acterized by increased genetic expression of P-glycoprotein (P-gp), which acts as

Impact of the cyclooxygenase system on doxorubicin-induced

Oct 22, 2004 hepatocytes by stimuli also known to induce COX-2 expression in several cell types, such as reactive oxygen species or some cytokines (Ziemann et al., 1999), suggesting a role of the COX system in regulating mdr1-type P-glycoprotein expression. COX-2 and the more constitutively